Uptravi (selexipag) / J&J 
Welcome,         Profile    Billing    Logout  
 17 Diseases   8 Trials   8 Trials   676 News 


12345678910»
  • ||||||||||  Uptravi (selexipag) / J&J
    Journal:  Combination drug therapy in pulmonary hypertension: switch from selexipaq to intravenous trepostinil (Pubmed Central) -  Dec 5, 2024   
    The primary endpoint (reaching "low-risk" status) was achieved in 12/21 (57.1%) patients (one further patient remained in "low-risk" status). These data indicate (despite the small number of patients) that even with established triple therapy, clinical improvement in individual patients is possible by switching from selexipag to intravenous treprostinil.
  • ||||||||||  Uptravi (selexipag) / J&J
    Cost Effectiveness of Selexipag Versus Placebo for Patients With Pulmonary Arterial Hypertension in Singapore () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_3150;    
    In overcoming the concerns of sustained efficacy in the blood while maintaining high selectivity for the IP receptor, CS585 represents a novel approach for the anti-platelet treatment of thrombotic diseases, with the potential to augment the therapeutic options for patients suffering from diseases like thrombosis, VTE, MI, stroke, and PAH. At the current price, selexipag is unlikely to be cost effective for treating patients with PAH in Singapore, when compared to placebo.
  • ||||||||||  Review, Journal:  New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Pubmed Central) -  Sep 30, 2024   
    Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
  • ||||||||||  Retrospective data, Review, Journal:  Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. (Pubmed Central) -  Sep 25, 2024   
    Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
  • ||||||||||  Uptravi (selexipag) / J&J
    Clinical, Journal:  Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension. (Pubmed Central) -  Sep 23, 2024   
    This study found that early selexipag addition to ERA plus PDE5i was associated with a reduction in risk of hospitalization and disease progression. These findings suggest that delays in selexipag initiation likely contribute to suboptimal patient and health system outcomes.
  • ||||||||||  Uptravi (selexipag) / J&J
    Journal, Adherence:  Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension. (Pubmed Central) -  Aug 19, 2024   
    There were no significant differences in patient outcomes, i,e, persistence (time to discontinuation) and risk of all-cause and PAH-related hospitalization across ID groups. The findings in this diverse, real-world population of patients with PAH reinforced an individualized approach to the dosing scheme to maximize benefit-risk and achieve the highest tolerated dose with selexipag similar to findings from the GRIPHON trial and other studies.
  • ||||||||||  midodrine hydrochloride / Generic mfg.
    HEMODYNAMIC EFFECTS OF MIDODRINE IN PULMONARY ARTERIAL HYPERTENSION (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3939;    
    Midodrine was well tolerated and safe with no adverse hemodynamic effects including bradycardia. CLINICAL IMPLICATIONS: Midodrine can be safely used in hospitalized PAH patients undergoing adjustment of their medications with no appreciable hemodynamic compromise.
  • ||||||||||  Uptravi (selexipag) / J&J
    CHARTING THE COURSE: PULMONARY HYPERTENSION AND THE DECISION TO INITIATE THERAPY (Convention Center Exhibit Hall: Poster Area 4) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3024;    
    Group 1 PAH patients' who benefit from triple therapy at baseline, may not tolerate the same degree of pulmonary vasodilation when there is an acute pulmonary process ongoing (i.e. pneumonia, significant atelectasis, acute CHF). In these circumstances, VQ mismatch will be heightened leading to respiratory decompensation.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Review, Journal:  Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review. (Pubmed Central) -  Jun 4, 2024   
    This difference is reflected in labeled indications. Given differences in trial- and real-world outcomes, number of prior therapies, and dosing, personalizing the choice of oral PPA is critical to maximizing the benefit for individual patients.
  • ||||||||||  Uptravi (selexipag) / J&J
    Real-world experience with selexipag in patients with pulmonary arterial hypertension in North America and Europe (PS-29; Poster board no. 19) -  May 31, 2024 - Abstract #ERS2024ERS_4270;    
    P=N/A
    The 1-year Kaplan-Meier (KM) survival estimates were 100% for low-risk patients, 96% for intermediate-low, 91% for intermediate-high, and 59% for high-risk (Figure 1). In North American and European clinical practices, patients initiated selexipag across all risk strata, with an overall 1-year KM survival estimate of 93%.
  • ||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Uptravi (selexipag) / J&J
    Assessment of Group 1 PAH patients on triple therapy clinical four risk strata outcome in a UAE centre (PS-29; Poster board no. 18) -  May 31, 2024 - Abstract #ERS2024ERS_4269;    
    All patients escalated to triple combination therapy by Prostacyclin analogues (Treprostinil IV/SQ, selexipag/iloprost inhaled) as third agent for atleast 3 months as best available therapy.1-,3-,5-year cumulative survival probability for Idiopathic was 95%(95%CI,75-92%),CTD 83%(95%CI,54-80%),CHD100%(95 CI,54-80%). Many patients remain in intermediate-high and high-risk category despite optimal triple therapy.Novel therapy pathway is needed for optimal clinical target.
  • ||||||||||  Uptravi (selexipag) / J&J
    Real-world experience of elderly patients with pulmonary arterial hypertension (PAH) initiating selexipag (EXPOSURE/EXTRACT studies) (PS-29; Poster board no. 17) -  May 31, 2024 - Abstract #ERS2024ERS_4268;    
    In the overall population, the median (Q1, Q3) exposure period was longer (13.0 [4.1, 29.0] months), fewer patients discontinued selexipag (41%), including 167 (17%) due to tolerability/AE, and one-year KM survival estimate was higher (92%); 116 patients died. These data suggest selexipag is predominately initiated as triple combination therapy in elderly patients, with consideration needed for managing side effects to improve tolerability.
  • ||||||||||  Uptravi (selexipag) / J&J, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Patients with pulmonary arterial hypertension: insights from the INSPECTIO study (PS-29; Poster board no. 16) -  May 31, 2024 - Abstract #ERS2024ERS_4267;    
    During the study, the number of noninvasive, low-risk parameters increased or remained stable in most pts. The therapy optimization based on risk assessment resulted in great value in the management of PAH.
  • ||||||||||  Uptravi (selexipag) / J&J, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Real-world evidence on pulmonary arterial hypertension: interim analysis from the Italian observational study INSPECTIO (Station 5 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_4963;    
    This study confirms that a noninvasive low-risk profile can be achieved with current combination PAH therapy. The modest or absent changes in echocardiographic and hemodynamic parameters suggest that treatment of PAH in real world is yet to be improved; on the other hand, the optimization of therapy in a significant portion of patients can possibly account for the improvement or stabilization observed.
  • ||||||||||  Winrevair (sotatercept) / BMS, Merck (MSD)
    Journal:  Sotatercept (Winrevair) for pulmonary arterial hypertension. (Pubmed Central) -  May 2, 2024   
    No patients discontinued selexipag; four patients received decreased doses due to flushing (n?=?1), drug interactions (n?=?2), or increased frequency of nose bleeds (n?=?1). No abstract available
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Preclinical, Journal:  Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists. (Pubmed Central) -  Apr 1, 2024   
    A literature survey indicated that few previously evaluated compounds (e.g., latanoprost, timolol, pilocarpine, brimonidine, dorzolamide, cromakalim analog (CKLP1), losartan, tissue plasminogen activator, trans-resveratrol, sodium 4-phenyl acetic acid, etc.) in various animal models of steroid-induced OHT were able to match the effectiveness of misoprostol, PF-04217329 or butaprost. Since a common feature of the latter compounds is their relatively high affinity and potency at the EP2-PG receptor sub-type, which activates the production of intracellular cAMP in target cells, our studies suggest that drugs selective for the EP2-PG receptor may be suited to treat corticosteroid-induced OHT.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Trial completion, Trial completion date, Trial primary completion date:  SOMBRERO: A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study (clinicaltrials.gov) -  Mar 27, 2024   
    P3,  N=43, Completed, 
    Since a common feature of the latter compounds is their relatively high affinity and potency at the EP2-PG receptor sub-type, which activates the production of intracellular cAMP in target cells, our studies suggest that drugs selective for the EP2-PG receptor may be suited to treat corticosteroid-induced OHT. Active, not recruiting --> Completed | Trial completion date: Sep 2028 --> Nov 2023 | Trial primary completion date: Dec 2025 --> Nov 2023
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Exploring and managing pulmonary hypertension in congenital heart defects: a challenging path (Moderated ePosters 3) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_2109;    
    Despite its lower representativeness in clinical trials, CHD remains an important cause for PH with a significant impact in mortality and CV admissions. Physical performance status, as evaluated by 6MWD, was seen as the most significant prognostic factor in our population, and those with less capacity displayed a far worse prognosis, reinforcing its importance in initial evaluation and need for early therapeutic intervention.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Real-world results of selexipag in treating pulmonary hypertension in a portuguese population (ePosters screen 19) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_1360;    
    The majority of patients demonstrated improvement or stability in WHO functional class, and selexipag-related side effects were manageable. With a low incidence of hospitalization for PAH-related complications and no reported mortality during the follow-up period, our findings suggest a promising profile for selexipag in real-world clinical practice.